Zhejiang Medicine Co Ltd
SSE:600216

Watchlist Manager
Zhejiang Medicine Co Ltd Logo
Zhejiang Medicine Co Ltd
SSE:600216
Watchlist
Price: 13.33 CNY -0.6% Market Closed
Market Cap: 12.8B CNY
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Zhejiang Medicine Co Ltd stock under the Base Case scenario is 23.02 CNY. Compared to the current market price of 13.33 CNY, Zhejiang Medicine Co Ltd is Undervalued by 42%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
23.02 CNY
Undervaluation 42%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.4
P/S
P/S
Price to Sales
1.4
vs History
74
vs Industry
62
Median 3Y
1.4
Median 5Y
1.6
Industry
2.4
Forward
1.3
More Details
8.8
P/E
P/E
Price to Earnings
8.8
vs History
98
vs Industry
34
Median 3Y
20.8
Median 5Y
18.7
Industry
20.5
Forward
11.8
More Details
8.5
P/OCF
P/OCF
Price to OCF
8.5
vs History
98
vs Industry
30
Median 3Y
15
Median 5Y
15
Industry
15.6
More Details
16.2
P/FCFE
P/FCFE
Price to FCFE
16.2
vs History
30
vs Industry
9
Median 3Y
-41.9
Median 5Y
-23.1
Industry
23.1
More Details
1.2
P/B
P/B
Price to Book Value
1.2
vs History
76
vs Industry
54
Median 3Y
1.3
Median 5Y
1.4
Industry
2
More Details
1.2
EV/S
EV/S
Enterprise Value to Sales
1.2
vs History
73
vs Industry
65
Median 3Y
1.2
Median 5Y
1.4
Industry
2.5
Forward
1.1
More Details
2.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.7
vs History
98
vs Industry
54
Median 3Y
3.4
Median 5Y
3.7
Industry
4.9
More Details
7.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
7.2
vs History
98
vs Industry
23
Median 3Y
20.7
Median 5Y
18.5
Industry
12.3
Forward
4.5
More Details
7.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
7.2
vs History
98
vs Industry
27
Median 3Y
20.7
Median 5Y
18.5
Industry
15.5
Forward
8
More Details
7.3
EV/OCF
EV/OCF
Enterprise Value to OCF
7.3
vs History
98
vs Industry
32
Median 3Y
12.6
Median 5Y
12.8
Industry
14.1
More Details
13.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
13.1
vs History
50
vs Industry
12
Median 3Y
-57.9
Median 5Y
13.1
Industry
17.5
More Details
1.1
EV/IC
EV/IC
Enterprise Value to IC
1.1
vs History
73
vs Industry
52
Median 3Y
1.1
Median 5Y
1.3
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
Zhejiang Medicine Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Zhejiang Medicine Co Ltd
SSE:600216
12.8B CNY 1.4 8.8 7.2 7.2
US
Eli Lilly and Co
NYSE:LLY
696.2B USD 14.2 62.7 33.8 36.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
371B USD 4.2 17 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.8 19.5 12.9 14.7
CH
Roche Holding AG
SIX:ROG
204.9B CHF 3.4 24.8 9.3 10.9
CH
Novartis AG
SIX:NOVN
178.1B CHF 4 16.7 9.9 13.2
UK
AstraZeneca PLC
LSE:AZN
158.8B GBP 3.8 27.2 130.4 196.6
US
Merck & Co Inc
NYSE:MRK
191.1B USD 3 11 8.2 10
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
116.5B EUR 1.3 9.2 5.1 5.9
P/E Multiple
Earnings Growth PEG
CN
Zhejiang Medicine Co Ltd
SSE:600216
Average P/E: 21.9
8.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
62.7
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.5
18%
1.1
CH
Roche Holding AG
SIX:ROG
24.8
32%
0.8
CH
Novartis AG
SIX:NOVN
16.7
17%
1
UK
AstraZeneca PLC
LSE:AZN
27.2
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.2
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Zhejiang Medicine Co Ltd
SSE:600216
Average EV/EBITDA: 394.2
7.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.8
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.3
6%
1.6
CH
Novartis AG
SIX:NOVN
9.9
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.4
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.2
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.1
8%
0.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Zhejiang Medicine Co Ltd
SSE:600216
Average EV/EBIT: 1 697.2
7.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.7
14%
1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
13.2
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
196.6
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.9
14%
0.4

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.